Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

European Journal of Paediatric Neurology, published by Elsevier Science Ltd, is a premier academic journal dedicated to advancing the field of paediatric neurology. With its ISSN 1090-3798 and E-ISSN 1532-2130, this journal serves as a vital resource for researchers, clinicians, and students alike, focusing on the latest findings and innovative treatments in paediatric neurological disorders. The journal has established itself as a leading publication in its field, achieving a Q1 classification in Pediatrics, Perinatology and Child Health, and holding a reputable Q2 status in Clinical Neurology as of 2023. Positioned within the top 88th percentile in Pediatrics and the 76th percentile in Clinical Neurology according to Scopus ranks, it publishes rigorous peer-reviewed articles that contribute significantly to clinical practice and research. Although not open access, the journal provides vital insights into the complexities of neurological conditions affecting the pediatric population, making it an essential tool for scholars and professionals striving to improve child health outcomes. With a publication trajectory spanning from 1997 to 2024, it continues to be at the forefront of paediatric neurological research, inspiring innovation and collaboration in the scientific community.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

REVUE NEUROLOGIQUE, published by MASSON EDITEUR, is a prestigious academic journal that plays an essential role in the field of neurology. With a rich history spanning from 1946 to the present, this journal focuses on both foundational and clinical aspects of neurology, underscoring its significance within the medical community. Holding an impressive Q2 ranking in both general and clinical neurology categories as of 2023, REVUE NEUROLOGIQUE is recognized for its contribution to advancing neurological science, as evidenced by its Scopus rankings, with a notable position in the 62nd percentile for clinical neurology. The journal fosters an environment for rigorous research and is instrumental for professionals and scholars aiming to stay abreast of the latest developments in neurological disorders and treatments. Although it is not an open-access publication, it offers a wealth of vital research through its issues, appealing to those engaged in both clinical practice and academic research in neurology.

SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.

Advances in Rheumatology is a premier open-access journal published by BMC, dedicated to advancing the field of rheumatology through high-quality, peer-reviewed research. Launched in 2018, the journal has quickly established itself within the academic community, achieving a commendable Q2 ranking in the category of Rheumatology as of 2023 and ranking #34 out of 73 in the Scopus Medicine Rheumatology listings, placing it in the 54th percentile. With a focus on innovative treatments, patient care, and the latest in rheumatological research, the journal provides a platform for researchers and clinicians to disseminate their findings and foster collaborative advancements in this critical area of medicine. Recognized for its accessibility, the journal follows an open-access model, ensuring that research is freely available to a global audience. With a commitment to high standards of academic rigor, Advances in Rheumatology plays a vital role in enhancing the understanding and treatment of rheumatic diseases, making it an invaluable resource for researchers, professionals, and students alike.

Schizophrenia, published by NATURE PORTFOLIO, is a pioneering open-access journal established in 2022, dedicated to advancing the scientific understanding of schizophrenia and its associated disorders. With its commitment to disseminating high-quality research without barriers, this journal aims to provide a platform for innovative studies, reviews, and meta-analyses that enhance clinical practices and therapeutic approaches. The journal is strategically located in Berlin, Germany, a hub for mental health research and innovation. By facilitating open exchange among researchers, professionals, and students, Schizophrenia aspires to be at the forefront of the global discourse on psychiatric disorders, driving forward critical advancements that can translate into improved patient care and outcomes. With a focus on promoting the latest findings in epidemiology, neurobiology, pharmacology, and psychosocial interventions, this journal is poised to become an essential resource for scholars and practitioners alike, eager to make significant contributions to the field.

The JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, published by AMER PSYCHIATRIC PUBLISHING, INC, stands as a pivotal resource in the interdisciplinary fields of psychiatry, neurology, and mental health. With a history spanning from 1989 to 2024, this esteemed journal, identified by the ISSN 0895-0172 and E-ISSN 1545-7222, provides a platform for cutting-edge research and clinical insights into neuropsychiatric disorders. As of 2023, the journal is recognized in Q2 quartiles for Medicine (miscellaneous), Neurology (clinical), and Psychiatry and Mental Health, showcasing its significant impact within these domains, as evidenced by its Scopus rankings placing it in the 67th and 65th percentiles respectively. The journal emphasizes the importance of advancing knowledge through empirical studies, case reports, and reviews, making it an invaluable asset for researchers, clinicians, and students dedicated to understanding the complexities of the human brain and its psychological manifestations. Although the journal does not currently offer open access, it remains essential for those seeking to stay at the forefront of neuropsychiatric advancements.